Monograph Details
|
|
Neoplasms
> Hormones and antagonists
|
|
EULEXIN |
| Manufacturer |
|
Schering Corporation |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antiandrogen. |
| Generic Name |
|
Flutamide 125mg; caps. |
| Indications |
|
In combination with LHRH agonists (GnRH analogues) in locally confined stage B2–C and stage D2 metastatic prostate carcinoma. |
| Children |
|
Not applicable. |
| Adults |
|
250mg every 8 hrs. |
| Contraindications |
|
Severe hepatic impairment. ALT ≥2xULN: not recommended. |
| Precautions |
|
Monitor liver function (at baseline, monthly for first 4 months, then periodically, and if liver dysfunction occurs; if ALT >2xULN or jaundice occurs, discontinue and monitor closely until resolution. Monitor prostate specific antigen (PSA). Consider monitoring methemoglobin levels in patients susceptible to aniline toxicity (e.g., G6PD deficiency, smokers, hemoglobin M disease). Pregnancy (Cat.D); not for use in women. |
| Interactions |
|
Monitor warfarin. |
| Adverse Reactions |
|
Diarrhea, hot flashes, loss of libido, impotence, GI disturbances, gynecomastia, rash, edema, hypertension, CNS effects, blood dyscrasias, urine discoloration, liver failure. |
| How Supplied |
|
Caps—180, 500 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
